MA37405A1 - Composés hétérocyclyle - Google Patents

Composés hétérocyclyle

Info

Publication number
MA37405A1
MA37405A1 MA37405A MA37405A MA37405A1 MA 37405 A1 MA37405 A1 MA 37405A1 MA 37405 A MA37405 A MA 37405A MA 37405 A MA37405 A MA 37405A MA 37405 A1 MA37405 A1 MA 37405A1
Authority
MA
Morocco
Prior art keywords
compounds
formula
heterocyclyl compounds
relates
present
Prior art date
Application number
MA37405A
Other languages
English (en)
Inventor
Bhavesh Dave
Rakesh Kumar Banerjee
Samiron Phukan
Abhijit Datta Khoje
Rajkumar Hangarge
Jitendra Sambhaji Jadhav
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37405(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MA37405A1 publication Critical patent/MA37405A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)

Abstract

La présente invention concerne des composés hétéroaryle en tant qu'inhibiteurs de mek. L'invention comprend des composés hétéroaryle de formule i, leurs tautomères et des sels pharmaceutiquement acceptables, des combinaisons avec un médicament approprié et des compositions pharmaceutiques de ceux-ci. La présente invention concerne également un procédé de préparation desdits composés et leur utilisation thérapeutique. (formule i) (i)
MA37405A 2012-03-14 2013-03-11 Composés hétérocyclyle MA37405A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14
PCT/IB2013/051915 WO2013136254A1 (fr) 2012-03-14 2013-03-11 Composés hétérocyclyle

Publications (1)

Publication Number Publication Date
MA37405A1 true MA37405A1 (fr) 2016-03-31

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
MA37405A MA37405A1 (fr) 2012-03-14 2013-03-11 Composés hétérocyclyle
MA37400A MA37400B1 (fr) 2012-03-14 2013-03-11 Composés hétérocyclyle en tant qu'inhibiteurs de mek

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA37400A MA37400B1 (fr) 2012-03-14 2013-03-11 Composés hétérocyclyle en tant qu'inhibiteurs de mek

Country Status (36)

Country Link
US (5) US9428499B2 (fr)
EP (2) EP2834236B1 (fr)
JP (3) JP6093384B2 (fr)
KR (4) KR20140138910A (fr)
CN (4) CN104203947A (fr)
AP (2) AP3834A (fr)
AU (4) AU2013234009B2 (fr)
BR (1) BR112014022713B1 (fr)
CA (2) CA2865167C (fr)
CL (2) CL2014002411A1 (fr)
CO (2) CO7170131A2 (fr)
CR (2) CR20140464A (fr)
CU (2) CU24272B1 (fr)
DK (2) DK2834236T3 (fr)
DO (2) DOP2014000204A (fr)
EA (2) EA029768B1 (fr)
ES (2) ES2741896T3 (fr)
GE (2) GEP201706774B (fr)
GT (2) GT201400196A (fr)
HK (2) HK1202538A1 (fr)
IL (2) IL234559A (fr)
IN (2) IN2014MN01754A (fr)
MA (2) MA37405A1 (fr)
MX (3) MX355474B (fr)
MY (2) MY174188A (fr)
NI (2) NI201400107A (fr)
NZ (2) NZ629432A (fr)
PE (2) PE20141973A1 (fr)
PH (2) PH12014502041B1 (fr)
PL (1) PL2834237T3 (fr)
SG (2) SG11201405007QA (fr)
TN (2) TN2014000357A1 (fr)
TR (1) TR201811976T4 (fr)
UA (2) UA114907C2 (fr)
WO (2) WO2013136249A1 (fr)
ZA (1) ZA201406186B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
NZ629432A (en) 2012-03-14 2017-01-27 Lupin Ltd Heterocyclyl compounds as mek inhibitors
ME02651B (fr) 2012-06-13 2017-06-20 Incyte Holdings Corp Composés tricycliques substitués utilisés comme inhibiteurs de fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA2909207C (fr) 2013-04-19 2021-11-02 Incyte Corporation Heterocycles bicycliques utilises en tant qu'inhibiteurs de fgfr
CA2927635C (fr) * 2013-10-25 2021-07-20 Shanghai Hengrui Pharmaceutical Co., Ltd. Derives pyridiques de cetone, leur procede de preparation et leur application pharmaceutique
WO2016009306A1 (fr) * 2014-07-15 2016-01-21 Lupin Limited Composés hétérocyclyles utilisés comme inhibiteurs de mek
WO2016035008A1 (fr) * 2014-09-04 2016-03-10 Lupin Limited Dérivés de pyridopyrimidine utilisés comme inhibiteurs de mek
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
AU2018390927B2 (en) * 2017-12-21 2023-01-12 Boehringer Ingelheim International Gmbh Novel benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors
WO2019213544A2 (fr) 2018-05-04 2019-11-07 Incyte Corporation Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
BR112021024532A2 (pt) 2019-06-19 2022-05-24 Boehringer Ingelheim Int Terapia combinada anticâncer
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
BR112022001678A2 (pt) * 2019-07-30 2022-05-03 Edvince Ab Inibidor mek, uso de um inibidor mek, método de tratar ou reduzir o risco de desenvolver um acidente vascular cerebral em um sujeito, composição, e, kit de partes
EP3797899A1 (fr) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Dispositif et procédé de détection d'un mouvement d'un corps dans une installation industrielle
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
WO2021146424A1 (fr) 2020-01-15 2021-07-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN116234806A (zh) 2020-06-02 2023-06-06 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
JP2024514127A (ja) 2021-04-09 2024-03-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗がん剤療法
AU2022258968A1 (en) * 2021-04-16 2023-10-19 Ikena Oncology, Inc. Mek inhibitors and uses thereof
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
WO2023099592A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh 2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer
WO2023099624A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh 2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer
TW202337432A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
WO2023099623A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh 2-amino-3-cyano-thiophènes annelés et dérivés pour le traitement du cancer
WO2023099620A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Composés de dégradation de kras comprenant des 2-amino-3-cyano thiophènes annelés
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
PL220952B1 (pl) * 2002-01-22 2016-01-29 Warner Lambert Co 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
AU2004293018B2 (en) 2003-11-19 2010-02-18 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
MXPA06014478A (es) * 2004-06-11 2007-03-21 Japan Tobacco Inc Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer.
AU2009344690A1 (en) 2009-04-21 2011-10-27 Novartis Ag Heterocyclic compounds as MEK inhibitors
NZ629432A (en) 2012-03-14 2017-01-27 Lupin Ltd Heterocyclyl compounds as mek inhibitors

Also Published As

Publication number Publication date
CU24335B1 (es) 2018-04-03
ES2684517T3 (es) 2018-10-03
DK2834237T3 (en) 2018-08-27
EP2834237B1 (fr) 2018-06-06
CN107698585A (zh) 2018-02-16
JP6630771B2 (ja) 2020-01-15
SG11201405006PA (en) 2014-10-30
AU2017200493B2 (en) 2018-03-29
EA201491671A1 (ru) 2014-12-30
WO2013136249A1 (fr) 2013-09-19
UA114907C2 (uk) 2017-08-28
KR20190073597A (ko) 2019-06-26
AU2017200493A1 (en) 2017-02-16
PE20141974A1 (es) 2014-12-12
WO2013136254A1 (fr) 2013-09-19
US9969731B2 (en) 2018-05-15
CO7160029A2 (es) 2015-01-15
EA201491672A1 (ru) 2014-12-30
ES2741896T3 (es) 2020-02-12
UA114906C2 (uk) 2017-08-28
CL2014002412A1 (es) 2015-03-06
KR20140138910A (ko) 2014-12-04
JP6093384B2 (ja) 2017-03-08
KR102240101B1 (ko) 2021-04-14
US9555035B2 (en) 2017-01-31
DK2834236T3 (da) 2019-08-26
NI201400107A (es) 2014-11-26
BR112014022713B1 (pt) 2021-09-08
JP2015514056A (ja) 2015-05-18
US20170112840A1 (en) 2017-04-27
IN2014MN01755A (fr) 2015-07-03
AU2013234014B2 (en) 2017-02-02
KR20140138911A (ko) 2014-12-04
PH12014502041A1 (en) 2014-11-24
CU20140109A7 (es) 2014-11-27
US20150299186A1 (en) 2015-10-22
PH12014502041B1 (en) 2014-11-24
MA37400B1 (fr) 2019-11-29
PH12014502040B1 (en) 2014-11-24
CU20140110A7 (es) 2014-11-27
MX2014010925A (es) 2015-04-10
CO7170131A2 (es) 2015-01-28
KR20190100472A (ko) 2019-08-28
CN104203947A (zh) 2014-12-10
MY174188A (en) 2020-03-12
HK1206020A1 (en) 2015-12-31
CU24272B1 (es) 2017-08-08
US20170101408A1 (en) 2017-04-13
CN108383836B (zh) 2021-11-12
GEP201706774B (en) 2017-11-27
TN2014000357A1 (en) 2015-12-21
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
GT201400195A (es) 2017-11-09
SG11201405007QA (en) 2014-10-30
NZ629442A (en) 2016-12-23
US20160331753A1 (en) 2016-11-17
AP3834A (en) 2016-09-30
PL2834237T3 (pl) 2018-11-30
MA37400A1 (fr) 2016-05-31
IL234559A (en) 2017-06-29
EP2834236A1 (fr) 2015-02-11
CA2865167A1 (fr) 2013-09-19
CA2865164A1 (fr) 2013-09-19
EP2834237A1 (fr) 2015-02-11
AP3859A (en) 2016-10-31
CL2014002411A1 (es) 2015-04-06
IL234560A (en) 2017-06-29
DOP2014000204A (es) 2015-02-15
AU2013234014A1 (en) 2014-09-25
EA029768B1 (ru) 2018-05-31
NZ629432A (en) 2017-01-27
ZA201406186B (en) 2016-06-29
US9827247B2 (en) 2017-11-28
US9573944B2 (en) 2017-02-21
MX355474B (es) 2018-04-16
JP2015509975A (ja) 2015-04-02
IN2014MN01754A (fr) 2015-07-03
US20150133424A1 (en) 2015-05-14
JP6431770B2 (ja) 2018-11-28
MX2014010928A (es) 2015-04-10
AP2014008008A0 (en) 2014-10-31
CR20140464A (es) 2014-11-28
GT201400196A (es) 2017-09-28
BR112014022713A2 (fr) 2017-06-20
CR20140463A (es) 2014-11-28
HK1202538A1 (en) 2015-10-02
AU2018202568A1 (en) 2018-05-10
CA2865164C (fr) 2021-06-08
KR102241111B1 (ko) 2021-04-15
CN104271577A (zh) 2015-01-07
MX355526B (es) 2018-04-20
AU2013234009B2 (en) 2016-10-27
AU2018202568B2 (en) 2019-05-09
TR201811976T4 (tr) 2018-09-21
CA2865167C (fr) 2019-08-06
MX366426B (es) 2019-07-08
GEP201706671B (en) 2017-05-25
EA028232B1 (ru) 2017-10-31
AP2014008009A0 (en) 2014-10-31
DOP2014000203A (es) 2015-02-15
NI201400108A (es) 2014-11-28
EP2834236B1 (fr) 2019-05-22
PE20141973A1 (es) 2014-12-12
CN108383836A (zh) 2018-08-10
AU2013234009A1 (en) 2014-09-25
PH12014502040A1 (en) 2014-11-24
JP2018115215A (ja) 2018-07-26
US9428499B2 (en) 2016-08-30

Similar Documents

Publication Publication Date Title
MA37405A1 (fr) Composés hétérocyclyle
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MA35348B1 (fr) 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
MA38138A1 (fr) Dérivés inédits de quinolone
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
GEP201706620B (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
IN2014MN02106A (fr)
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MA37886A1 (fr) Nouvelles pyridinones bicycliques
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
WO2014014794A3 (fr) Antagonistes des récepteurs aux minéralocorticoïdes
NZ611529A (en) Glucagon receptor modulators
MX2013003202A (es) Inhibidores de oxadiazol de la produccion de leucotrienos.
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA37999B1 (fr) Dérivés de macrolide, leur préparation et leur utilisation thérapeutique
IN2014MN02433A (fr)
MA37879B1 (fr) Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant